11 product centralized procurement won the bid for one year to achieve blood-returning letter Litai what to look forward to in the future

The performance continues to grow, Xinlitai has stepped out of the trough, and has begun to enter the rising period of innovative pharmaceutical companies?

On the evening of April 18, Xinlitai released the first-quarter results announcement, saying that the revenue in the first quarter of 2022 was about 935 million yuan, a year-on-year increase of 22.

This is that Xinlitai has achieved continuous quarterly performance growth since 2020 after suffering heavy losses in centralized procurement

The defeat is also concentrated, the success is also concentrated

As we all know, since 2018, the state has continuously deepened the implementation of the policy of centralized drug procurement with volume, and Xinli Taichong, which is enjoying the dividends of the era of generic drugs, is on the front line of centralized drug procurement with volume

Although its core product, clopidogrel, was selected at the price of 3.

However, with the in-depth expansion and promotion of centralized procurement, Xin Litai has almost been involved in the six rounds of national centralized procurement carried out in the past three years

In addition, in 2021, its innovative product, Xinlitan Allisartan Medoxomil, successfully renewed the National Medical Insurance Catalogue through medical insurance negotiation, which also helped drive the growth of Xinlitai's business

Xinlitai centralized procurement winning details table

Data source: Yaozhi Data

According to Litai's annual financial report, in 2021, Xinlitai's revenue is 3.

Innovation and transformation, the fruitful period has come

However, Xinlitai is also constantly seeking innovation and transformation, and is marching in the two directions of innovative drugs and high-end generic drugs

According to the financial report, Xinlitai currently has 48 research projects, including 26 chemical drugs (including 21 innovative projects), 15 biological drugs (including 10 innovative projects), and 7 research projects in the field of medical devices

Xinlitai drug research and development pipeline

Source: official website of the company

It is also worth noting that the shareholders meeting held by Xin Litai on April 18 stated that it will continue to increase investment in research and development.

Image credit: Snowball

According to analysis, after the Xinlitai teriparatide water injection was approved for the market in April, it is expected to complete 40 million in the whole year, plus about 40 million for powder injection.

Summarize

Xinlitai continued to focus on innovative R&D and investment, greatly improved its independent innovation and R&D capabilities, and rapidly enriched its product lines

References:

1.